DE2059514A1 - Diagnostisches Verfahren zum Nachweis von Hepatitis und Testreagenzien zur Durchfuehrung des Verfahrens - Google Patents
Diagnostisches Verfahren zum Nachweis von Hepatitis und Testreagenzien zur Durchfuehrung des VerfahrensInfo
- Publication number
- DE2059514A1 DE2059514A1 DE19702059514 DE2059514A DE2059514A1 DE 2059514 A1 DE2059514 A1 DE 2059514A1 DE 19702059514 DE19702059514 DE 19702059514 DE 2059514 A DE2059514 A DE 2059514A DE 2059514 A1 DE2059514 A1 DE 2059514A1
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- serum
- reagent
- test
- concentration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000012360 testing method Methods 0.000 title claims description 50
- 239000003153 chemical reaction reagent Substances 0.000 title claims description 42
- 238000000034 method Methods 0.000 title claims description 36
- 238000002405 diagnostic procedure Methods 0.000 title claims description 15
- 238000001514 detection method Methods 0.000 title claims description 10
- 208000006454 hepatitis Diseases 0.000 title description 65
- 231100000283 hepatitis Toxicity 0.000 title description 64
- 210000002966 serum Anatomy 0.000 claims description 60
- 238000006243 chemical reaction Methods 0.000 claims description 35
- 239000000243 solution Substances 0.000 claims description 32
- 239000002245 particle Substances 0.000 claims description 29
- 102000006395 Globulins Human genes 0.000 claims description 23
- 108010044091 Globulins Proteins 0.000 claims description 23
- 238000010998 test method Methods 0.000 claims description 22
- 208000037319 Hepatitis infectious Diseases 0.000 claims description 21
- 208000005252 hepatitis A Diseases 0.000 claims description 21
- 208000002672 hepatitis B Diseases 0.000 claims description 16
- 230000002458 infectious effect Effects 0.000 claims description 14
- 238000004062 sedimentation Methods 0.000 claims description 13
- 239000004793 Polystyrene Substances 0.000 claims description 9
- 239000007853 buffer solution Substances 0.000 claims description 9
- 229920002223 polystyrene Polymers 0.000 claims description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 235000002639 sodium chloride Nutrition 0.000 claims description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical group [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 7
- 230000001900 immune effect Effects 0.000 claims description 7
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 5
- 239000004471 Glycine Substances 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 4
- 150000002333 glycines Chemical class 0.000 claims description 4
- 208000015181 infectious disease Diseases 0.000 claims description 4
- 239000000969 carrier Substances 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 3
- 230000008014 freezing Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 239000007787 solid Substances 0.000 claims description 3
- 239000012266 salt solution Substances 0.000 claims description 2
- 238000003756 stirring Methods 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims 2
- 239000003513 alkali Substances 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 159000000011 group IA salts Chemical class 0.000 claims 1
- 210000004369 blood Anatomy 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 108010074605 gamma-Globulins Proteins 0.000 description 23
- 239000004816 latex Substances 0.000 description 16
- 229920000126 latex Polymers 0.000 description 16
- 208000019423 liver disease Diseases 0.000 description 13
- 239000000203 mixture Substances 0.000 description 10
- 239000011550 stock solution Substances 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 239000000725 suspension Substances 0.000 description 8
- 238000011534 incubation Methods 0.000 description 7
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- 230000004520 agglutination Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000005194 fractionation Methods 0.000 description 6
- 210000004185 liver Anatomy 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 239000000376 reactant Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 230000007882 cirrhosis Effects 0.000 description 4
- 208000019425 cirrhosis of liver Diseases 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 210000003743 erythrocyte Anatomy 0.000 description 4
- 229940072221 immunoglobulins Drugs 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 210000002381 plasma Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000009589 serological test Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010018910 Haemolysis Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 230000001788 irregular Effects 0.000 description 3
- 239000002689 soil Substances 0.000 description 3
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 2
- 206010004659 Biliary cirrhosis Diseases 0.000 description 2
- 208000027932 Collagen disease Diseases 0.000 description 2
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 2
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 239000010836 blood and blood product Substances 0.000 description 2
- 229940125691 blood product Drugs 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000004927 clay Substances 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 229960004544 cortisone Drugs 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960002449 glycine Drugs 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 230000008105 immune reaction Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012956 testing procedure Methods 0.000 description 2
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 101100121625 Caenorhabditis elegans rhi-1 gene Proteins 0.000 description 1
- 206010009208 Cirrhosis alcoholic Diseases 0.000 description 1
- 241000543381 Cliftonia monophylla Species 0.000 description 1
- 108010032597 Cohn fraction II Proteins 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010029719 Nonspecific reaction Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 241000219995 Wisteria Species 0.000 description 1
- 240000003290 Wisteria sinensis Species 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 208000010002 alcoholic liver cirrhosis Diseases 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 229940125717 barbiturate Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 238000009739 binding Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- GICLSALZHXCILJ-UHFFFAOYSA-N ctk5a5089 Chemical compound NCC(O)=O.NCC(O)=O GICLSALZHXCILJ-UHFFFAOYSA-N 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014665 endocarditis Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 238000002594 fluoroscopy Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 201000006747 infectious mononucleosis Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000379 polymerizing effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 235000015170 shellfish Nutrition 0.000 description 1
- 238000005397 spin echo fourier transformation Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000006379 syphilis Diseases 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/82—Hepatitis associated antigens and antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S436/00—Chemistry: analytical and immunological testing
- Y10S436/826—Additives, e.g. buffers, diluents, preservatives
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/806—Antigenic peptides or proteins
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/81—Carrier - bound or immobilized peptides or proteins and the preparation thereof, e.g. biological cell or cell fragment as carrier
- Y10S530/812—Peptides or proteins is immobilized on, or in, an organic carrier
- Y10S530/815—Carrier is a synthetic polymer
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/829—Blood
- Y10S530/83—Plasma; serum
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88326169A | 1969-12-08 | 1969-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE2059514A1 true DE2059514A1 (de) | 1971-07-15 |
Family
ID=25382275
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19702059514 Pending DE2059514A1 (de) | 1969-12-08 | 1970-12-03 | Diagnostisches Verfahren zum Nachweis von Hepatitis und Testreagenzien zur Durchfuehrung des Verfahrens |
Country Status (10)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3992517A (en) * | 1975-02-19 | 1976-11-16 | Pfizer Inc. | Detection of hepatitis B surface antigen by latex agglutination |
| US6699722B2 (en) | 2000-04-14 | 2004-03-02 | A-Fem Medical Corporation | Positive detection lateral-flow apparatus and method for small and large analytes |
-
0
- BE BE759948D patent/BE759948A/xx unknown
-
1969
- 1969-12-08 US US883261A patent/US3697639A/en not_active Expired - Lifetime
-
1970
- 1970-10-20 NL NL7015336A patent/NL7015336A/xx unknown
- 1970-10-23 IL IL35517A patent/IL35517A0/xx unknown
- 1970-10-26 ZA ZA707267A patent/ZA707267B/xx unknown
- 1970-11-06 AU AU21987/70A patent/AU2198770A/en not_active Expired
- 1970-11-06 FR FR7040093A patent/FR2082972A5/fr not_active Expired
- 1970-11-12 ES ES385489A patent/ES385489A1/es not_active Expired
- 1970-11-26 GB GB1297295D patent/GB1297295A/en not_active Expired
- 1970-12-03 DE DE19702059514 patent/DE2059514A1/de active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2198770A (en) | 1972-05-11 |
| GB1297295A (enrdf_load_stackoverflow) | 1972-11-22 |
| ZA707267B (en) | 1972-05-31 |
| US3697639A (en) | 1972-10-10 |
| IL35517A0 (en) | 1970-12-24 |
| ES385489A1 (es) | 1976-01-01 |
| FR2082972A5 (enrdf_load_stackoverflow) | 1971-12-10 |
| BE759948A (fr) | 1971-06-07 |
| NL7015336A (enrdf_load_stackoverflow) | 1971-06-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE2522086C2 (de) | Reagenz zum Abtrennen und Bestimmen von in biologischen Fluiden vorhandenen AK:Ag-Komplexen | |
| DE3884979T2 (de) | Agglutinationsimmunotest und Satz zur Bestimmung einer mehrwertigen Immunspezies unter Verwendung einer gepufferten Salzwasch-Lösung. | |
| DE2512730A1 (de) | Verfahren zum nachweis einer immunologischen reaktion und zur bestimmung der konzentration immunologisch reaktiver biologischer teilchen sowie vorrichtung zur durchfuehrung des verfahrens | |
| DE3882058T2 (de) | Immunoreaktives Reagens, Verfahren zu seiner Herstellung und seine Verwendung zur Bestimmung einer immunoreaktiven Spezies. | |
| DE2651139C3 (de) | Reagens zur Durchführung eines Direktagglutinationstests zum Schwangerschaftsnachweis und Verfahren zu seiner Herstellung | |
| DE1648999C3 (de) | Verfahren zur immunochemischen Bestimmung von Antigenen und Antikörpern | |
| DE3002973C2 (enrdf_load_stackoverflow) | ||
| DE2134928B2 (de) | Immunologisches Reagens und Verfahren zu seiner Herstellung | |
| EP3438667B1 (de) | Bindungstest zur diagnose einer heparin-induzierten thrombozytopenie | |
| DE2604844C3 (de) | Verfahren zum Nachweis von Hepatitis B-Oberflächenantigen in menschlichem Blut | |
| DE2602068C2 (de) | Reagens zur Unlöslichmachung eines Antigen/Antikörper-Komplexes | |
| DE3105555C2 (enrdf_load_stackoverflow) | ||
| EP0039885B1 (de) | Verfahren und Reagens zum Nachweis von Fibrinmonomer | |
| DE69200460T2 (de) | Agglutinationskomplex zum Nachweis von Blutgruppen. | |
| EP1064557A2 (de) | Verfahren zum nachweis von antikörpern oder antigenen sowie zur blutgruppenbestimmung | |
| DE2059514A1 (de) | Diagnostisches Verfahren zum Nachweis von Hepatitis und Testreagenzien zur Durchfuehrung des Verfahrens | |
| DE68907365T2 (de) | Verfahren zur Bestimmung des Vorhandenseins leichter Ketten in Urinproben, Komplex von Vorbereitungen zur Erledigung des Verfahrens und damit verbundenes Reagenz. | |
| DE2608733A1 (de) | Reagens zur bestimmung von fibrinogen, fibrinspaltprodukten und fibrinogenspaltprodukten im blut und verfahren zur herstellung desselben | |
| DE2433246A1 (de) | Verbessertes verfahren fuer den nachweis und die reinigung von proteinen und antikoerpern und vorrichtung zu dessen durchfuehrung | |
| DE2517860C3 (de) | Verfahren zum Bestimmen des Pyrogengehalts in Proben | |
| DE4112999C2 (de) | Verfahren und Nachweismittel zum Nachweis einer Infektion mit dem Epstein-Barr Virus | |
| DE69117097T2 (de) | Testvorrichtungen | |
| EP0487459B1 (de) | Verfahren zum Nachweis von Antikörpern | |
| DE2404565A1 (de) | Verfahren zur durchfuehrung immunochemischer und serodiagnostischer testreaktionen | |
| DE2237204C3 (de) | Verfahren zum Nachweis des Australien-Antigens oder des Antikörpers hierzu in einer Blut-Testprobe |